report earn per share one-tim tax-reform charg
lower estim earn lower
expect due corpor partner royalti incom lower
estim oper expens higher estim estim
ep adjust modestli tax-reform expect
increas cash flow report reinvest capit expans
share repurchas potenti acquisit
total product sale in-lin estim result higher
estim sale epogen enbrel nuelasta kyproli xgeva prolia
offset lower estim sale aranesp blincyto repatha
sensipar
modestli lower estim dilut ep
less account slightli higher estim sg lower estim
interest incom slightli lower product sale decreas product
sale estim
full-year guidanc includ total revenu billion non-
gaap ep tax rate capit expenditur
expect approxim million
announc deploy repatri cash addit billion
share repurchas invest new manufactur facil addit
compani report continu invest pipelin also evalu
potenti acquisit provid growth acquisit interest would
focu area interest
use ep estim long-term earn growth industri
multipl arriv price target compar
prior target
biotechnolog
discov
develop manufactur market
cancer autoimmun
diseas specialti market
analyst certif import disclosur see disclosur appendix
estim dilut earn per share
grow compound annual rate next five
annual sale growth sg decreas
percentag sale expens decreas
modestli absolut basi expect volum increas
growth product continu increas market
penetr
estim revenu grow compound-annual-growth-rate per
year next five year dilut ep growth
per year believ posit long
growth recoveri matur product declin stabl level new
product continu grow pipelin produc addit
product addit dividend yield
estim sell price two experiment
product low price increas exist
product would meaning upsid earn
experiment compound launch sooner
estim would result addit upsid
repatha growth slow experiment therapi
biosimilar fail launch estim reduct
estim five-year compound-annual-growth-rate earn
earn
scenario estim stock could valu
rang next month
accord proprietari databas averag forward multipl biotechnolog sector past ten year
base consensu estim appli biotech group averag ratio fulli dilut ep forecast
growth rate along probabl adjust invest discount rate arriv
estim valu price target
believ greatest risk stock next five year disrupt continu success repatha fda
approv experiment therapi romosozumab erenumab success launch biosimilar abp abp abp
risk project repatha growth slow experiment therapi biosimilar fail launch estim
reduct estim five-year compound-annual-growth-rate earn earn per share
scenario estim stock could valu rang next month
continu rate amgen outperform new month price target
estim revenu grow compound annual rate
next five year continu believ posit long growth
recoveri matur product declin stabl level new product continu grow
pipelin produc addit product
estim dilut earn per share grow compound-annual-growth-rate next
five year basi ep estim stock
current trade price-to-earnings growth rate ratio averag
biotech group end amgen stock current trade price-to-earnings
multipl dividend yield add valu lower downsid risk
believ greatest risk stock next five year disrupt
continu success repatha use treat cardiac diseas failur fda
approv experiment therapi romosozumab osteoporosi erenumab
migrain disrupt success launch biosimilar abp abp
abp anti-vegf respect risk
project repatha growth slow experiment therapi biosimilar fail
launch estim reduct five-year compound-annual-growth-rate earn
earn scenario estim
stock could valu rang next month
valuat methodolog biotech compani depend development-
stage product meaning percentag estim futur earn growth
compound-annual-growth-rate greater base appli industri price-to-earnings
multipl pe growth rate ratio estim futur earn discount
valu base estim risk failur use biotechnolog group multipl
deriv averag price-to-earnings multipl ratio compani
profit sever year exhibit defin biotechnolog industri equal
weight stock biotechnolog compani posit earn
exhibit price earn ratio pe pe growth ratio calcul base
price group last day month earn per share estim wall street
analyst forward year therefor multipl calcul
divid price group estim ep divid growth rate
sourc data use calcul databas compil maintain
oppenheim co use estim fact set price quot servic
typic appli averag multipl futur estim earn determin
discount rate base compani stage develop use risk failur
base phase develop publish tuft center studi drug
develop base data failur rate potenti drug phase
develop approxim progress phase ii develop
failur rate approxim progress phase develop
approxim actual file approv food drug
administr failur rate
howev extens pipelin experiment therapi model
estim sale come experiment product remain
result current approv drug alreadi approv indic
experiment drug model romosozumab osteoporosi
erenumab migrain phase develop therefor result discount
per year probabl failur pre-fil plu probabl failur
file estim sale biosimilar develop abp
abp anti-vegf abp launch result
discount probabl failur commerci estim
sale combin impact experiment compound biosimilar
earn addit use invest rate per year use
probabl failur discount
conclus use biotech group averag ratio
earn growth rate estim arriv target price-to-earnings multipl
appli target multipl fulli dilut ep along
discount rate potenti failur develop stage product plu
discount invest return arriv price target
compar prior target
analysi
report earn per share one-tim tax-reform charg
lower estim earn lower
expect due corpor partner royalti incom lower estim
oper expens higher estim sg
higher anticip although acknowledg sg includ
extraordinari expens includ cost associ hurrican maria
total product sale in-lin estim result higher estim
sale epogen enbrel nuelasta kyproli xgeva prolia offset lower
estim sale aranesp blincyto repatha sensipar detail
analysi quarter outlin exhibit
exhibit analysi compani report oppenheim co estim continu next page
inc -nasdaq estim sale earn million except per share data estimatedactualactu vs opco bp consensusactu vs consensusi chang bp chang bp incom statement pipelin abp abp anti-vegf abp new product outperform
estimatedactualactu vs opco bp consensusactu vs consensusi chang bp chang bp incom statement product partner royalti good affiliates/oth share share per share per share compani data oppenheim co estimatesaddit inform avail upon request inc
gave guidanc confer call outlin
estim ep adjust modestli modestli
lower dilut ep less account slightli higher
estim sg lower estim interest incom slightli lower
product sale product sale estim decreas
detail list exhibit
billiongaap tax non-gaap tax millionamgen corpor guidanc outperform
exhibit updat outlook continu next page
inc amgn-nasdaq leah rush cannestim sale earningsoppenheim co million except per share bp priorrevisedchang bp priorrevisedchang bp priorrevisedchang bp incom statement pipelin abp abp anti-vegf abp new product amgen inc
priorrevisedchang bp priorrevisedchang bp priorrevisedchang bp priorrevisedchang bp incom statement product partner royalti good affiliates/oth share share per share per share compani data oppenheim co estimatesaddit inform avail upon request outperform
amgen announc websit
amgen inc product indicationpartner/ licenseiiiiiifiledapprovedmarketedhematology/oncologyamg myelomaamg tumorsamg myeloid leukemiaamg amlamg talimogen laherparepvec cancermetastat melanomaunresect melanomakrypoli carfilzomib small-cel lung cancerrelapsed/refractori mm dexamethasonerelapsed/refractori mm darzalex dexjanssenrelaps refractori mm lenalidomid dexnewli diagnos multipl myelomarelaps refractori multipl myelomaoprozomibhematolog malignanciesblincyto blinatumomab diffus larg b-cell lymphomaamgen-astellasadult relapsed/refractori ph allamgen-astellaspediatr relaps ph- cell allamgen-astellasrelapsed/refractori ph- cell allamgen-astellasxgeva denosumab non-smal cell lungbreast cancermultipl myelomasolid tumorsaranesp darbepoetin alfa mdspatient receiv myelosuppress chemotherapyvectibix panitumumab chemorefractori wt kra metastat crcfrontlin combo therapi folfoxnpl romiplostim chronic immun thrombocytopenianeulasta pegfilgrastim febril neutropenia myelosuppress therapyneupogen filgrastim neutropenia abp biosimilar cetuximab cancerallerganmvasi biosimilar bevacizumab cancerallerganabp biosimilar rituximab cancerallerganabp biosimilar trastuzumab cancer unit state allergancanc europ allerganpre-clinicalclin trial amgen inc
amgen announc websit
pipelin progress sinc octob present includ
repatha receiv fda approv prevent heart attack stroke
coronari revascular adult establish cardiovascular diseas
kyproli receiv fda approv treatment patient relaps
refractori multipl myeloma combin dexamethason januari
also receiv posit opinion ema recommend label variat
includ updat os date phase endeavor studi
xgeva receiv fda approv prevent sre patient multipl
european commiss approv expand indic nplate
includ treatment chronic immun idiopath thrombocytopenia purpura
patient one year age older
european commiss grant market author mvasi
biosimilar bevacizumab treatment cancer
phase studi aimovig erenumab met primari endpoint
secondari endpoint patient episod migrain experienc two
four previou prevent treatment failur due lack efficaci intoler
phase studi tezepelumab began enrol patient decemb
amgen inc product indicationpartner/ licenseiiiiiifiledapprovedmarketedinflamm lupu erythematosusastrazeneca lupu erythematosusastrazeneca diseasestezepelumab atop dermatitisastrazenecaenbrel etanercept pediatr chronic sever plaqu psoriasisrheumatoid arthriti psoriat arthriti plaqu psoriasisabp biosimilar adalimumab inflammatori diseas unit state inflammatori diseas europ abp biosimilar infliximab inflammatori diseasescardiovascular mecarbilheart failurecytokineticsrepatha evolocumab ldl-disordersamgen-astellashypercholesterolemia atherosclerot cardiovascular failurecorlanor ivabradin chronic heart failureneurosci diseasenovartisalzheim diseas studi start soon novartisaimovig erenumab migrain prophylaxisnovartismigrain prophylaxisnovartisgener medicineeven romosozumab osteoporosisamgen-astellasparsabiv etelcalcetid secondari hyperparathyroid ckdepogen epoetin alfa anemia sensipar cinacalcet secondari hyperparathyroid ckdprolia denosumab osteoporosispre-clinicalclin trial outperform
phase studi xgeva patient high-risk early-stag breast cancer
meet primari endpoint bone metastasis-fre surviv
fda decis file
amgen announc websit
updat sinc octob present includ
decemb announc fda accept prioriti review
sbla blincyto treatment mrd patient acut lymphoblast
leukemia pdufa target action date march
januari submit sbla fda variat market
author ema includ overal surviv data
studi product label
amgen announc websit
updat sinc octob present includ
report plan resubmit bla even fda
product candidateindicationfilingdecisionexpect timingxgevamultipl myelomalabel expansionpdufa februari expansionpdufa march multipl myelomasndalabel expansionpdufa april erenumab migrain preventionblafda approvalpdufa may proliaosteoporosissblalabel expansionpdufa may biosimilar herceptin cancerblafda approvalbufa may multipl myelomasndalabel candidateindicationfilingexpect time dataevenityosteoporosisresubmiss amgen inc
provid summari financi outlook full financi
model product detail avail upon request
exhibit summari model continu next page
inc -nasdaq leah rush cannoppenheim co million except per share statement pipelin abp abp anti-vegf abp new product outperform
total product partner royalti growth affiliates/oth share share per share per share sheet stockhold invest statementoper cash flow per cash flow per compani data oppenheim co estimatesaddit inform avail upon request inc
growth compani data oppenheim co estimatesaddit inform avail upon request outperform
